Cancer Therapy News and Research

RSS

New Australian drug shows positive response in patients with multiple myeloma blood cancer

Australian monoclonal antibody company, Immune System Therapeutics Limited (IST), today announced it would double patient recruitment in its Phase II trial for a breakthrough antibody treatment for terminal blood cancer.

16 Jun 2011

Adaptimmune melanoma trial opening

Adaptimmune announced today that it has opened a Phase I/II, two cohort, open label clinical trial in metastatic melanoma at Washington University, St. Louis, Missouri.

16 Jun 2011

State roundup: Mass. health spending's rise; huge Ky. hospital merger

A new report from the state Division of Health Care Finance and Policy shows that: ... "Spending per member on privately insured people grew 6 percent from 2007 to 2008 and another 10 percent from 2008 to 2009. This rate of growth was substantially higher than the increase in national personal health care expenditures per capita of 4.6 percent from 2008 to 2009. Spending by private payers also grew faster than spending by public payers".

16 Jun 2011

Varian receives marketing approval for TrueBeam image-guided radiotherapy and radiosurgery system in Japan

Varian Medical Systems, Inc., the world's leading manufacturer of medical technology for treating cancer with radiotherapy, announced today it has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the TrueBeam™ system for image-guided radiotherapy and radiosurgery in Japan.

15 Jun 2011

Nuvilex to acquire live cell encapsulation technology for multiple cancer therapies

Nuvilex, Inc. announced today it has entered into discussions to acquire the next generation live cell encapsulation technology that serves as the platform for multiple cancer therapies.

15 Jun 2011

Biomoda receives U.S. patent to expand the use of CyPath assay for treatment of cancer

Cancer diagnostics company Biomoda, Inc. received Notice of Allowance for a U.S. Patent issued today that expands on use of the CyPath assay to include patient response to cancer therapy during the treatment phase of the disease.

15 Jun 2011

Ventana Medical receives FDA approval for new breast cancer genetic test

The U.S. Food and Drug Administration today approved a new genetic test that will help health care professionals determine if women with breast cancer are HER2-positive and, therefore, candidates for Herceptin, a commonly used breast cancer treatment.

15 Jun 2011

UC Davis, Jackson Laboratory and NCI partner for human clinical trials on cancer

About nine out of 10 new cancer drugs successfully clear preclinical development hurdles, but then they fail in human clinical testing. A new partnership facilitated by SAIC-Frederick Inc. aims to help change that outcome.

13 Jun 2011

FDA accepts ZIOPHARM's IND for ZIN ATI-001 to treat melanoma

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today that the U.S. Food & Drug Administration has accepted the Company's investigational new drug application to begin clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate also known as Ad-RTS-IL-12 + AL, in oncology.

10 Jun 2011

Sulforaphane-rich foods safe and effective for preventing cancer

Sulforaphane, one of the primary phytochemicals in broccoli and other cruciferous vegetables that helps them prevent cancer, has been shown for the first time to selectively target and kill cancer cells while leaving normal prostate cells healthy and unaffected.

10 Jun 2011

Eliminating ABCB5-expressing cells crucial for successful colorectal cancer treatment

Researchers at Children's Hospital Boston have found a marker called ABCB5 that both tags a small proportion of cells within colorectal cancers and fuels resistance in those cells to standard treatments. The results indicate that eliminating ABCB5-expressing cells is crucial for successful colorectal cancer treatment, while adding to the growing body of evidence for a theory of cancer growth called the cancer stem cell hypothesis.

9 Jun 2011

NYU Cancer Institute scientists present new research findings at ASCO 2011

Experts from The Cancer Institute, an NCI-designated cancer center, at NYU Langone Medical Center presented new research findings at the 47th American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago, IL.

8 Jun 2011

Merck, Roche partner to develop cancer diagnostic assays

Merck, known outside the United States and Canada as MSD, and Roche today announced that they have entered into a collaboration focused on the application and development of diagnostic assays for use with Merck's investigational cancer therapy portfolio.

From Roche Sequencing and Life Science 7 Jun 2011

IsoRay completes Iotrex license agreement with Dr. Reddy's

IsoRay, Inc. announced today that it has completed a license agreement with Dr. Reddy's Laboratories for exclusive worldwide licensing rights to Iotrex, a liquid iodine radiation, for use in brain cancer treatment.

7 Jun 2011

OncoSec announces additional evaluation of ElectroImmunotherapy Phase I trial on melanoma

OncoSec Medical Incorporated, which is developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, announced today that additional evaluation of a previous Phase I trial provided further evidence that a DNA plasmid encoded to produce IL-12 delivered by electroporation into melanoma lesions induces responses to known and novel antigens, resulting in regression of local treated lesions as well as distant untreated lesions.

7 Jun 2011

Increases in VEGF-family markers in metastatic colorectal cancer patients associated with Avastin resistance

Circadian Technologies Limited announced today the presentation of data at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago USA associating resistance to Avastin with increases in plasma VEGF-C and D concentrations.

7 Jun 2011

Scientists discover key molecule that targets tumour blood vessels

Scientists at the Walter and Eliza Hall Institute have discovered a key molecule needed to kill the blood vessels that supply tumours.

7 Jun 2011

Faults in p53 gene could help predict beneficial drug combination for ovarian cancer

FAULTS in a gene commonly inactivated in many different types of cancer could be used to predict which drug combination ovarian cancer patients are most likely to benefit from, according to results presented at the American Society for Clinical Oncology.

7 Jun 2011

APP to commence marketing Letrozole Tablets for breast cancer in the U.S.

Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that APP Pharmaceuticals will immediately begin marketing Letrozole Tablets in the U.S., after the U.S. Food and Drug Administration granted approval to market the breast cancer treatment medication to Fresenius Kabi Oncology Limited.

7 Jun 2011

AstraZeneca receives AmeriCares' Power of Partnership Award for global health programs

AmeriCares has awarded its annual Power of Partnership Award to AstraZeneca for its outstanding commitment to increasing access to health care for people in need both here at home and throughout the developing world.

7 Jun 2011

Cancer Therapy News and Research

New Australian drug shows positive response in patients with multiple myeloma blood cancer

Adaptimmune melanoma trial opening

State roundup: Mass. health spending's rise; huge Ky. hospital merger

Varian receives marketing approval for TrueBeam image-guided radiotherapy and radiosurgery system in Japan

Nuvilex to acquire live cell encapsulation technology for multiple cancer therapies

Biomoda receives U.S. patent to expand the use of CyPath assay for treatment of cancer

Ventana Medical receives FDA approval for new breast cancer genetic test

UC Davis, Jackson Laboratory and NCI partner for human clinical trials on cancer

FDA accepts ZIOPHARM's IND for ZIN ATI-001 to treat melanoma

Sulforaphane-rich foods safe and effective for preventing cancer

Eliminating ABCB5-expressing cells crucial for successful colorectal cancer treatment

NYU Cancer Institute scientists present new research findings at ASCO 2011

Merck, Roche partner to develop cancer diagnostic assays

IsoRay completes Iotrex license agreement with Dr. Reddy's

OncoSec announces additional evaluation of ElectroImmunotherapy Phase I trial on melanoma

Increases in VEGF-family markers in metastatic colorectal cancer patients associated with Avastin resistance

Scientists discover key molecule that targets tumour blood vessels

Faults in p53 gene could help predict beneficial drug combination for ovarian cancer

APP to commence marketing Letrozole Tablets for breast cancer in the U.S.

AstraZeneca receives AmeriCares' Power of Partnership Award for global health programs

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News